Search

Your search keyword '"Thiel, Uwe"' showing total 160 results

Search Constraints

Start Over You searched for: Author "Thiel, Uwe" Remove constraint Author: "Thiel, Uwe"
160 results on '"Thiel, Uwe"'

Search Results

1. Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles.

2. Enhancing CHM1319 specific TCR-transgenic T cell cytotoxic effect on Ewing sarcoma cell lines

3. MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress

4. Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma

6. TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model

8. Figure S1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

9. Data from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

10. Supplementary Information 1 from The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

11. Data from STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors

12. Supplementary Methods, Figures 1-5, Tables 1-4 from STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors

13. Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function, and Upregulate Endogenous Retroelements

14. Viro-immunotherapy against Ewing sarcoma: synergistic antitumor effects of the oncolytic adenovirus XVir-N-31 with T cell receptor-transgenic T cells and cell cycle inhibition

15. The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma

16. T Cells Directed against the Metastatic Driver Chondromodulin-1 in Ewing Sarcoma: Comparative Engineering with CRISPR/Cas9 vs. Retroviral Gene Transfer for Adoptive Transfer

17. No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy

18. No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy

19. Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function

22. Abstract PR05: T-cell receptor (TCR)-based immunotherapy in pediatric malignancy: Addressing the challenge of early metastasis and low immunogenicity

24. MHC Class I-Restricted TCR-Transgenic CD4+ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo

25. Exosomes transmit retroelement RNAs to drive inflammation and immunosuppression in Ewing Sarcoma

26. Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma

27. Abstract A28: Donor lymphocyte infusion after allogeneic stem cell transplantation is a feasible therapy option with acceptable toxicity rates in patients with refractory Ewing’s sarcoma and rhabdomyosarcoma

28. Systematic identification of cancer-specific MHC-binding peptides with RAVEN

30. Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma

31. Abstract B38: Ewing sarcoma regression without GVHD by allo-MHC/CHM1 specific T cells

32. Muscarinic Acetylcholine Receptor M3 Mutation Causes Urinary Bladder Disease and a Prune-Belly-like Syndrome

33. Systematic identification of cancer-specific MHC-binding peptides with RAVEN

36. Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells

39. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow

40. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow

41. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens

42. Abstract 3202: Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity

43. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T Cells specifically inhibit Ewing sarcoma growth in vitro and in vivo

44. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity

45. Stem cell rescue from irradiation of multiple tumor sites combined with high-dose chemotherapy, followed by reduced intensity conditioning and allogeneic stem cell transplantation in patients with advanced pediatric sarcomas: Preliminary results of the MetaEICESS 2007 protocol.

46. Stem cell rescue from irradiation of multifocal bone disease combined with high-dose chemotherapy and reduced intensity conditioned haplodisparate stem cell transplantation in advanced pediatric sarcomas: Update of MetaEICESS 2007.

47. First identification of Ewing's sarcoma‐derived extracellular vesicles and exploration of their biological and potential diagnostic implications

48. STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors

49. Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.

50. Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitroand in vivo

Catalog

Books, media, physical & digital resources